We improve on nature.



Our first-in-class bicistronic-S1S3 technology platform enhances M6P content on lysosomal enzymes for both recombinant enzyme and gene therapies, which improves enzyme uptake across target tissues, allowing us to restore the enzymatic activity within this natural pathway.

Based on a scientific breakthrough by researchers Stuart Kornfeld and Lin Liu in 2017, we successfully created a technology platform to regulate the M6P levels on lysosomal enzymes, allowing us to potentially treat even LSDs where the required enzymes have naturally low M6P levels, such as mucopolysaccaridosis IIIB (MPS IIIB) and alpha-mannosidosis. Because M6P has greater affinity to bind to the M6P receptors on the lysosome, we are able to develop targeted, individualized, and effective medicines, either enzyme replacement therapy (ERT) or gene therapy, to treat the specific LSD; we also have the opportunity to improve treatment options for other LSDs that currently have approved therapies.

With our ability to regulate M6P, we apply a rational approach and decades of battle-tested experience to identify the right modality and the right dosage at the right time for patients with LSDs.

M6P Therapeutics Science Overview Animation 

The below animation provides an overview of M6P Therapeutics’ bicistronic-S1S3 technology platform, how it works in target lysosomal storage disorders, and its potential.


Background Information

What is Phosphorylation?

Phosphorylation is the process of adding a phosphate group to a target molecule. For many years, research into treatments for LSDs focused on finding a way to add a phosphate group to the sixth location on a target mannose molecule to create mannose 6-phosphate (M6P).

The following diagram (1) depicts the steps necessary to complete this process.


GlcNAc-1-phosphotransferase is a naturally occurring enzyme that resides in the Golgi apparatus within cells. GlcNAc-1-phosphotransferase catalyzes the transfer of GlcNAc-1-phosphate from uridine diphosphate (UDP) onto certain terminal mannose residues of the N-linked oligosaccharides on enzymes destined for the lysosome.

N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (NAGPA), also known as uncovering enzyme, removes the covering GlcNAc group, thereby exposing mannose 6-phosphate.


The Breakthrough Discovery: S1-S3 Variant of GlcNAc-1-phosphotransferase

Although scientists have understood the process for phosphorylating lysosomal enzymes for some time, no one has been able to control GlcNAc-1-phosphotransferase to enhance the level of M6P on enzyme replacement therapy (ERT) enzymes. The problem is that GlcNAc-1-phosphotransferase is difficult to control in laboratory conditions and manufacturing processes.

In 2017, Stuart Kornfeld and Lin Liu achieved a breakthrough discovery when they created a controllable variant of GlcNAc-1-phosphotransferase — the S1-S3 variant. When cells were given both the DNA sequences for the S1-S3 variant and various lysosomal enzymes, the cells were able to produce the lysosomal enzymes with high M6P content. Drs. Kornfeld and Liu published their results in a leading peer-reviewed journal(2), clearly showing that the S1-S3 variant can enhance the M6P content of lysosomal enzymes and that the resulting lysosomal enzymes are better able to bind to cell surface receptors.

* p<.05; ** p<.01; LAMAN: lysosomal acid alpha-mannosidase for alpha-mannosidosis. GAA: acid alpha-glucosidase for Pompe disease. GLA: alpha-galactosidase A for Fabry disease. GBA: beta-glucocerebrosidase for Gaucher disease.


Bicistronic vector platform

With the S1-S3 variant technology, we can co-express separate DNA sequences for the S1-S3 variant and the lysosomal enzyme in the same cell to create M6P-rich lysosomal enzymes. While this is a significant advancement, we took science one step further.

Our goal was to create a general vehicle whereby the S1-S3 variant of GlcNAc-1-phosphotransferase would be expressed along with any therapeutic lysosomal enzyme. As an analogy, we wanted to build a pickup truck with a payload bed that could hold any enzyme, so the resulting fully loaded truck leads to an M6P-rich enzyme. Scientifically speaking, we aimed to create a single DNA expression vector that would simultaneously express two separate genes. Such a vector, with two DNA sequences, or cistrons, is known as a bicistronic vector.

Our molecular biologists have done some phenomenal work and have created this bicistronic platform. Using this platform, we have already created six lysosomal enzymes rich in M6P content.



1. Kang et al. Mutations in the Lysosomal Enzyme – Targeting Pathway and Persistent Stuttering. N Engl J Med 2010;362:677-685.

2. Lin Liu, Wang-Sik Lee, Balraj Doray, and Stuart Kornfeld. Engineering of GlcNAc-1-Phosphotransferase for Production of Highly Phosphorylated Lysosomal Enzymes for Enzyme Replacement Therapy,
Mol Ther Methods Clin Dev. 2017 Jun 16; 5: 59–65.